Experic LLC eyes importing THC – public input deadline looms
Published Date: 8/26/2026
Notice
Summary
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Application to Import Three Controlled Drugs
On July 17, 2026, Experic LLC applied to be registered to import three controlled substances: tetrahydrocannabinols (code 7370, Schedule I), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431, Schedule I), and nabilone (code 7379, Schedule II). The company says the imports would be for internal research and clinical trial purposes only.
No Commercial Finished Dosage Imports Allowed
If approved, the registration will not allow Experic LLC to import Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale. Approval is limited to activities consistent with 21 U.S.C. 952(a)(2).
Sept 25, 2026 Comment and Hearing Deadline
Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before September 25, 2026 using https://www.regulations.gov or by mail to the Drug Enforcement Administration hearing addresses listed in the notice. Comments submitted through the portal will receive a Comment Tracking Number upon successful submission.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
2026-17276, Importer of Controlled Substances Application: Biopharmaceutical Research Company
Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Previous / Next Documents
Previous: 2026-17384, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Request for Comment; Consolidated Child Restraint System Registration for Defect Notifications and Labeling
In compliance with the Paperwork Reduction Act of 1995 (PRA), this notice announces that the Information Collection Request (ICR) summarized below will be submitted to the Office of Management and Budget (OMB) for review and approval. The ICR describes the nature of the information collection and its expected burden. This document request for comments on a reinstatement and revision of a previously- approved information collection on Child Restraint System Registration for Defect Notifications and Labeling. A Federal Register Notice with a 60-day comment period soliciting comments on the following information collection was published on December 5, 2023 (88 FR 84514). No comments were received.
Next: 2026-17386, Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC
Chemtos, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.